Antibody

AntibodySun Yat-sen UniversityPhase 2

효능 ORR 89%임상시험 2상태 DISCONTINUED

Adebrelimab & SHR2554 (Adebrelimab & SHR2554)

Relapsed or Refractory Peripheral T Cell Lymphoma; NKTCL · FRα

AntibodystaleJanssenPhase 3

Daratumumab (CT-P44, CT-P44(Daratumumab))

Refractory or Relapsed Multiple Myeloma · FRα

#FR#Antibody#Phase3#항체#면역항체+3

AntibodystaleJanssenApproved

CYCLOSPORINE VS INFLIXIMAB (CYCLOSPORINE VS INFLIXIMAB)

Ulcerative Colitis; Steroid Refractory · FRα

#FR#Antibody#Approved#항체#면역항체+4

AntibodystaleEli LillyPhase 2

Cetuximab Sarotalocan Sodium (Cetuximab Sarotalocan Sodium)

Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma · FRα

Intravenously (Daratumumab, Daratumumab (Intravenously))

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · FRα

임상시험 1상태 DISCONTINUED

daratumumab (Darzalex, Daratumumab with dexamethasone)

Relapsed/Refractory Multiple Myeloma · FRα

효능 ORR 18.4%임상시험 1상태 ACTIVE

daratumumab (Darzalex, Daratumumab, thalidomide and dexamethasone)

Relapse and / or Refractory Myeloma · FRα

AntibodystaleJanssenPhase 3

Daratumumab (Darzalex Faspro, Darzalex Faspro(Daratumumab))

Refractory or Relapsed Multiple Myeloma · FRα

#FR#Antibody#Phase3#항체#면역항체+3

AntibodystaleAmgenPhase 2

Xgeva (Denosumab, Denosumab (Xgeva))

Bone Cyst Aneurysmal; Pathological Fracture · FRα

AntibodystaleUniversity of Southern Californ…Phase 2

효능 ORR 5%임상시험 1상태 ACTIVE

Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab (Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab)

Colorectal Cancer · FRα

AntibodystaleInstitut für Klinische Krebsfor…Phase 2

임상시험 1상태 DISCONTINUED

Glofitamab as Consolidation therapy (Glofitamab as Consolidation therapy)

Relapsed /Refractory DLBCL · FRα

AntibodystaleInstitut für Klinische Krebsfor…Phase 2

Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy (Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy)

Relapsed /Refractory DLBCL · FRα

AntibodystaleChinese Academy of Medical Scie…Phase 2

Ibrutinib Combined With Rituximab (Ibrutinib Combined With Rituximab)

DLBCL; MYD88 Gene Mutation · FRα

Infliximab and Basiliximab (Infliximab and Basiliximab)

Graft Versus Host Disease; Steroid Refractory GVHD · FRα

AntibodystaleSanofiPhase 2

효능 ORR 10%임상시험 1상태 DISCONTINUED

Isatuximab SC-OBDS (Isatuximab SC-OBDS)

Plasma Cell Myeloma Refractory · FRα

AntibodystaleMonopteros Therapeutics Inc.Phase 1

pembrolizumab (Keytruda, MPT-0118 + pembrolizumab)

Solid Tumor, Adult; Advanced Solid Tumor · FRα

#FR#Antibody#Phase1#항체#면역항체+5

AntibodystaleRochePhase 2

Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab (Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab)

Refractory Metastatic Colorectal Cancer · FRα

daratumumab (Darzalex, Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab)

Relapsed/Refractory Multiple Myeloma · FRα

AntibodystaleAbGenomics B.V Taiwan BranchPhase 2

Neihulizumab Treatment (Neihulizumab Treatment)

Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation · FRα